VPTDF - Ventripoint Expands to Address the Needs of Companion Animals
(TheNewswire)
Toronto, Ontario - The Newswire -January 11, 2021 - Ventripoint Diagnostics Ltd.(" Ventripoint " or the " Company "), (TSXV:VPT ) ( OTC:VPTDF) announces that it has entered into a Collaboration Agreementwith the Veterinary Hospital at the North Carolina State University(NCSU) to test and evaluate the use of the VMS+in echocardiography of canines with the goal of expanding thistechnology to all animals.
Dr. Bruce W Keene, DVM, MSc, DACVIM of NC StateVeterinary Medicine commented, “NC StateCardiology is pleased to be a part of the development and preliminarytesting of a potential veterinary application ofthe Ventripoint echocardiography system. Moreaccurate and complete echocardiographic estimates of cardiacdimensions and volumes would provide a major advance forveterinary echocardiography. The potential to use Ventripoint'sartificial intelligence-based software to allow us to reliablyvisualize the heart in 3-dimensions from routinely acquired2-dimensional data would contribute significantly to the casemanagement of both congenital and acquired heart diseases inanimals.”
A Bank of America survey found 37% of Americans haveadopted a pet since the start of the COVID pandemic. All theseanimals will need some form of veterinary care as they grow older. A ccording to theAmerican Veterinary Medical Association (AVMA), the pet dog populationin the United States is estimated to be 77 million dogs ( AVMA Pet Ownership and Demographics Sourcebook, 2017-2018Edition) with approximately 10% of all dogshaving heart disease (estimated to be 7.8 million dogs; Dogs and Heart Disease: An Overview; www.pethealthnetwork.com ) . The trueprevalence of cardiovascular disease is likely underestimated becausemost domestic animals do not receive a cardiac workup.
This is a natural progression for Ventripoint andevolution of our technology. With this study, Ventripoint candiversify its product portfolio and expand our innovative technologyto advance cardiac care for animals. The aim is to provide asolution for veterinarians that will ultimately be applicable to allanimals.
“Companion animals have heart problems, like theirowners and so we are delighted to broaden our products to includeveterinary services,” stated Dr. George Adams, Executive-Chairman ofVentripoint. “Initial studies at NCSU have shown the VMS+3.0 canaccurately reconstruct and measure the function of canine hearts andthis more in-depth evaluation in collaboration with NCSU will verifythe results.”
There are approximately 30,000 veterinary practices inthe United States according to the American Veterinary MedicalAssociation. Thousands of these clinics offer echocardiographyservices without having a board-certified veterinary cardiologist onstaff. The ease of use of the VMS+3.0 will allow a better initialassessment of dogs and if necessary, the easy transfer of the studiesto a board-certified veterinary cardiologist for furtherreview.
The ease of use of the VMS+3.0 will allow a betterinitial assessment of dogs and if necessary, the easy transfer of thestudies to a board-certified veterinary cardiologist for furtherreview.
Equipping and training veterinarians on cardiacassessment using 2D ultrasound and the VMS+3.0 analysis system wouldenable many more companion animals to be properly evaluated andtreated. Like all cardiac disease, early detection and treatment iscritical to achieving a long-term outcome.
Ventripoint is expanding to improve the care of allhumans and their best friends.
About the North Carolina State University Veterinary Hospital and College of Veterinary Medicine
The Veterinary Hospital is an integrated healthcare center for companion, equine and farm animals. We exist tofurther the teaching mission of the College of Veterinary Medicine andto provide state-of-the-art patient care. About23,000 cases, primarily companion animals and horses , are diagnosed and treated annually bythe Veterinary Hospital. The College involves some 155 faculty, 400staff members, and it enrolls more than 300 Doctor of VeterinaryMedicine (DVM) students, 80 graduate students, and 75 interns andresidents. A component of these research activities, the Center forComparative Medicine and Translational Research (CCMTR) is a communityof more than 100 scientists who are involved in collaborative studieswith government, private, and other academic researchers to advancethe knowledge and practical applications that improve animal and humanhealth. According to the 2019, U.S. News &World Report, the North Carolina StateUniversity College of Veterinary Medicine wasranked 4 th in the USA ( https://www.usnews.com/best-graduate-schools/top-health-schools/veterinarian-rankings ).
About Ventripoint DiagnosticsLtd.
Ventripoint has become anindustry leader in the application of AI (Artificial Intelligence) toechocardiography. Ventripoint's VMS products are powered by itsproprietary KBR technology, which is the result of a decade ofdevelopment and provides accurate volumetric cardiac measurementsequivalent to MRI. This affordable, gold-standard alternative allowscardiologists greater confidence in the management of their patients.Providing better care to patients serves as a springboard and basicstandard for all of Ventripoint's products that guide our futuredevelopments. In addition, VMS+ is versatile and can be used with allultrasound systems from any vendor supported by regulatory marketapprovals in the U.S., Europe and Canada.
For further information, pleasecontact:
Dr. George Adams
Tel: 519- 803-6937
Neither the TSX Venture Exchange nor its RegulationServices Provider (as that term is defined in the policies of the TSXVenture Exchange) accepts responsibility for the adequacy or accuracyof this news release.
Forward Looking Statements
This news release contains forward-looking statementsand forward-looking information within the meaning of applicablesecurities laws. The use of any of the words "expect","anticipate", "continue", "estimate","objective", "ongoing", "may","will", "project", "should","believe", "plans", "intends'' and similarexpressions are intended to identify forward-looking information orstatements. The forward-looking statements and information are basedon certain key expectations and assumptions made by the Company.Although the Company believes that the expectations and assumptions onwhich such forward-looking statements and information are based arereasonable, undue reliance should not be placed on the forward-lookingstatements and information because the Company can give no assurancethat they will prove to be correct.
Since forward-looking statements and informationaddress future events and conditions, by their very nature theyinvolve inherent risks and uncertainties. Actual results could differmaterially from those currently anticipated due to a number of factorsand risks. Factors which could materially affect such forward-lookinginformation are described in the risk factors in the Company's mostrecent annual management's discussion and analysis that is availableon the Company's profile on SEDAR at www.sedar.com. Readers arecautioned that the foregoing list of factors is not exhaustive. Theforward-looking statements included in this news release are expresslyqualified by this cautionary statement. The forward-looking statementsand information contained in this news release are made as of the datehereof and the Company undertakes no obligation to update publicly orrevise any forward-looking statements or information, whether as aresult of new information, future events or otherwise, unless sorequired by applicable securities laws.
Copyright (c) 2021 TheNewswire - All rights reserved.